The National Brain Tumor Society is providing $200,000 to Oncoceutics to support a phase II clinical trial of ONC201, the first imipridone dopamine receptor D2 antagonist, in a molecular subset of high grade gliomas.
The Foundation for the NIH has opened nominations for its 2020 Trailblazer Prize for clinician-scientists, recognizing the outstanding contributions of early-career clinician-scientists whose work has the potential to lead to innovations in patient care—or has already done so.
A report by the Office of the Surgeon General finds that more than two-thirds of United States adult cigarette smokers report interest in quitting cigarette smoking; and the majority of adult cigarette smokers in the U.S. have tried to quit during the past year.
Stand Up To Cancer has launched two initiatives to increase minority representation in cancer clinical trials by amending its grant application requirements and funding a new research team focused on diversity and inclusion.
FDA granted accelerated approval to Tazverik (tazemetostat) for the treatment of adults and pediatric patients ages 16 and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
FDA has granted priority review for GlaxoSmithKline's Biologics License Application seeking approval of belantamab mafodotin for patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.
Myriad Genetics has submitted a supplementary premarket approval application to FDA for its BRACAnalysis CDx test as a companion diagnostic to AstraZeneca's and Merck's PARP inhibitor Lynparza for men with metastatic castration-resistant prostate cancer.
Evotec SE and Indivumed GmbH entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer. The goal of the precision medicine collaboration is to deliver highly effective treatments for NSCLC patients.
Health Canada has approved Keytruda in combination with Inlyta for first-line treatment of patients with advanced renal cell carcinoma.
The independent data monitoring committee of the phase III SANET-p study of surufatinib in advanced neuroendocrine tumors has recommended that the study end early as the pre-defined primary endpoint of progression free survival had already been met.
